Arrowhead Pharma: EU Approval for REDEMPLO Triggers Massive Volume

The European Commission grants formal market authorization for REDEMPLO, which as the only therapy for chylomicronemia syndrome no longer requires a time-consuming genetic test. Excellent study data demonstrate an 80% reduction in triglycerides, which provides the innovative drug with excellent long-term commercial prospects in Europe. Institutional investors are massively accumulating the stock, as this fundamental medical breakthrough completely overshadows the temporarily weak quarterly revenues of the biotech company. Arrowhead Pharmaceuticals...